TTH with all due respect give me one (1) example in the last 10 years where a new product in the regulated healthcare space has been launched successfully by “distributors” without the originator of the product spending massive dollars on marketing and launch. It simply doesn’t happen!
I probably should have been a bit more specific and used the term “successfully” launch. PXS has launched Aridol recently but one would not say it has been a success! When the next 2,000 Truscreen devices are shipped with the cash RECEIVED by PLT I’ll eat my words.
Self sampling is going to take even more dollars to launch successfully than Truscreen and in any case who in their right mind would spend such a sum if they didn’t hold an exceptionally strong IP position in the space yet alone just a distribution deal?
Yes CareHPV is a “future”product and Truscreen has been around for a decade. I’m pretty confident on where the sales legder will stand in comparing the 2 products in say 2 years from now...remember as you all admit PLT and Truscreen is a 20011/2012 story.
Finally, re CareHPV being focussed on Asian “woop-woop” villages the very countries that many of the people on this thread spruik and project telephone like sales numbers from their massive populations have demographic dispersions very much like “woop-woop”villages.
You can’t have it both ways either re-define Truscreen’s target market or acknowledge the need to tailor a product that is friendly to “woop-woop” areas!
As Red rightly says we’ll know about the merits of GBI versus PLT in due course and then it will be all so easy with the benefit of hindsight.
Good luck and caveat emptor
cheers
PS..I dont have a day job and this appears to be good sport besides my golf game!
PLT Price at posting:
12.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)